Trial · NCT00948298

Effect of Vitamin D3 on Vascular Function

NCT00948298, Not applicable, Completed, Charles Drew University of Medicine and Science; results first posted 2018-07-17

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Effect of Vitamin D3 on Vascular Function. Trials, record NCT00948298. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00948298

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Vitamin D3 on Vascular Function
NCT number: NCT00948298
Status: Completed
Phases: Not applicable
Enrollment: 130 participants, actual
Lead sponsor: Charles Drew University of Medicine and Science
Conditions: Vitamin D Deficiency
Interventions: Vitamin D, Placebo
First posted: 2009-07-29
Last updated: 2018-07-17
Results first posted: 2018-07-17

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Pulse Wave Velocity for Vascular Stiffness	12 Weeks	The primary outcome variable is pulse wave velocity (PWV) for vascular stiffness. The hypothesis is that a greater decrease in the PWV will occur with the Vitamin D3 treatment. PWV is the speed at which the arterial pulse wave travels through the arteries in the cardiovascular system. It is considered the gold standard for the assessment of arterial elastance (stiffness) and determined by radial artery applanation tonometry using the SphygmoCor device.
Secondary	Changes in Sitting and 24 Ambulatory Blood Pressure	12 weeks	Improved vascular function as determined by measuring sitting and 24 Hour Ambulatory Blood Pressure.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Pulse Wave Velocity for Vascular Stiffness	12 Weeks		m/s	MEAN
SECONDARY	Changes in Sitting and 24 Ambulatory Blood Pressure	12 weeks		mmHg	MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Pulse Wave Velocity for Vascular Stiffness	Placebo		29.3	Standard Deviation 11.0	m/s
Pulse Wave Velocity for Vascular Stiffness	Vitamin D		27.6	Standard Deviation 11.0	m/s
Changes in Sitting and 24 Ambulatory Blood Pressure	Placebo	Blood Pressure (Systolic)	125.8	Standard Deviation 13.3	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Vitamin D	Blood Pressure (Systolic)	126.9	Standard Deviation 15.0	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Placebo	Blood Pressure (Diastolic)	82.2	Standard Deviation 9.2	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Vitamin D	Blood Pressure (Diastolic)	81.1	Standard Deviation 12.0	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Placebo	24 Hour Blood Pressure (Systolic)	128.4	Standard Deviation 14.0	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Vitamin D	24 Hour Blood Pressure (Systolic)	127.4	Standard Deviation 16.4	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Placebo	24 Hour Blood Pressure (Diastolic)	83.9	Standard Deviation 10.1	mmHg
Changes in Sitting and 24 Ambulatory Blood Pressure	Vitamin D	24 Hour Blood Pressure (Diastolic)	82.0	Standard Deviation 11.6	mmHg

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	65
Overall Study	STARTED	Vitamin D	65
Overall Study	COMPLETED	Placebo	55
Overall Study	COMPLETED	Vitamin D	60
Overall Study	NOT COMPLETED	Placebo	10
Overall Study	NOT COMPLETED	Vitamin D	5

Source ClinicalTrials.gov

Adverse events64

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hemoglobin = 9.6 G/DL	Blood and lymphatic system disorders	Placebo	0	65	0
other	Hemoglobin = 9.6 G/DL	Blood and lymphatic system disorders	Vitamin D	1	65	1
other	High Platelet Count = 493 Thousand/UL	Blood and lymphatic system disorders	Placebo	1	65	1
other	High Platelet Count = 493 Thousand/UL	Blood and lymphatic system disorders	Vitamin D	0	65	0
other	Hematocrit = 30.2%	Blood and lymphatic system disorders	Placebo	0	65	0
other	Hematocrit = 30.2%	Blood and lymphatic system disorders	Vitamin D	1	65	1
other	Elevated WBC = 14.9	Blood and lymphatic system disorders	Placebo	0	65	0
other	Elevated WBC = 14.9	Blood and lymphatic system disorders	Vitamin D	1	65	1
other	Low White Blood Cell Count = 2.9	Blood and lymphatic system disorders	Placebo	0	65	0
other	Low White Blood Cell Count = 2.9	Blood and lymphatic system disorders	Vitamin D	1	65	1

1 to 10 of 64Source ClinicalTrials.gov

See all 64 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	65
Total, all-cause mortality	Vitamin D	0	65
Total, other adverse events	Placebo	12	65
Total, other adverse events	Vitamin D	14	65
Total, serious adverse events	Placebo	4	65
Total, serious adverse events	Vitamin D	4	65

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U54RR022762	Drew RCMI Translational Research Network	NORRIS, KEITH C	CHARLES R. DREW UNIVERSITY OF MED & SCI	NATIONAL CENTER FOR RESEARCH RESOURCES	2007 to 2011

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Vitamin D vs Placebo: deaths from any cause	Trial comparisons
Vitamin D vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00948298

GET https://conductscience.org/api/trials/v1/NCT00948298/events?page=2

API reference For AI assistants